Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance
| Autor: | Wing Sun Chow, YC Woo, Karen Siu-Ling Lam, David T W Lui, Chp Lee, Kristy Man‐yi Yeung, Alan Chun Hong Lee, Kathryn C.B. Tan, Carol H.Y. Fong, V W K Chau, Joanne K.Y. Lam |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Bone mineral
medicine.medical_specialty endocrine system diseases Bone density business.industry Endocrinology Diabetes and Metabolism nutritional and metabolic diseases 030209 endocrinology & metabolism medicine.disease Impaired fasting glucose Bone remodeling Impaired glucose tolerance 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin resistance Trabecular bone score 030220 oncology & carcinogenesis Internal medicine Medicine Prediabetes business |
| Zdroj: | Journal of Endocrinological Investigation. 44:523-530 |
| ISSN: | 1720-8386 |
| Popis: | Findings on trabecular bone score (TBS), an index of bone quality, have been reported in prediabetes defined by impaired fasting glucose or HbA1c. Here, we assessed the bone mineral density (BMD) and TBS in prediabetes individuals with impaired glucose tolerance (IGT), and investigated the association of these bone parameters with serum levels of fibroblast growth factor 21 (FGF21), a hormone implicated in bone metabolism and with higher levels in IGT. Chinese postmenopausal women aged 55–80 years, without diabetes, were recruited from the Hong Kong Cardiovascular Risk Factor Prevalence Study in 2016–2018. Normal glucose tolerance (NGT) was defined by fasting glucose |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink